1. Home
  2. PUBM vs PROK Comparison

PUBM vs PROK Comparison

Compare PUBM & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$9.21

Market Cap

406.5M

Sector

Technology

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$2.32

Market Cap

417.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
PROK
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
406.5M
417.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PUBM
PROK
Price
$9.21
$2.32
Analyst Decision
Buy
Strong Buy
Analyst Count
10
4
Target Price
$18.45
$6.25
AVG Volume (30 Days)
1.1M
1.4M
Earning Date
11-10-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$288,382,000.00
$744,000.00
Revenue This Year
N/A
$918.66
Revenue Next Year
$0.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.01
$0.46
52 Week High
$17.32
$7.13

Technical Indicators

Market Signals
Indicator
PUBM
PROK
Relative Strength Index (RSI) 54.40 44.95
Support Level $8.91 $2.04
Resistance Level $9.24 $2.25
Average True Range (ATR) 0.35 0.19
MACD -0.00 0.04
Stochastic Oscillator 61.62 45.90

Price Performance

Historical Comparison
PUBM
PROK

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: